Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Key Highlights
- ➤FDA pre-IND interaction supports ERNA-101’s advancement toward ovarian cancer clinical development
- ➤ERNA-101’s IND-enabling studies assess safety, biodistribution and tumor-homing characteristics
- ➤ERNA-101 engineers induced mesenchymal stromal cells to express IL-7 and IL-15
- ➤Ernexa plans first-in-human clinical evaluation after completing regulatory and clinical preparation
Expert Statements
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“ERNA-101 is moving through a critical transition from preclinical development toward the clinic, and our focus is on executing each step with discipline”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“The progress we are making across regulatory planning, IND-enabling development and clinical preparation is bringing us closer to the point where we can begin evaluating this technology in patients.”
Christopher Rohde, Member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform
“Our goal from the beginning was to build a cell therapy platform that could combine the flexibility of cellular engineering with an approach designed for practical, off-the-shelf use,”
Christopher Rohde, Member of Ernexa’s Scientific Advisory Board and developer of the technology underlying the Company’s platform
“ERNA-101 reflects that strategy by pairing an engineered cell platform with immune-modulating biology intended to act where it matters most, within the tumor microenvironment.”
Robert Pierce, Chief Scientific Officer of Ernexa Therapeutics
“The importance of the platform is not simply what it is engineered to do, but whether the biology translates into meaningful and reproducible activity,”
Robert Pierce, Chief Scientific Officer of Ernexa Therapeutics
“Our preclinical work is helping us understand that biology in greater depth and build the scientific package needed to support ERNA-101’s advancement into the clinic.”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“We believe ERNA-101 represents more than a single development program”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“Our immediate priority is to advance the asset into the clinic, but the broader opportunity lies in demonstrating what this platform can potentially enable across oncology.”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“That is the value we are working to unlock.”
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation
Discussion features Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer
Get started
Create a free account to read the full story.